TY -的T1 -为什么炎性表型出现necessary for successful drug evaluation in asthma and COPD JF - European Respiratory Journal JO - Eur Respir J SP - 891 LP - 892 DO - 10.1183/09031936.00038713 VL - 42 IS - 4 AU - Gibson, Peter G. Y1 - 2013/10/01 UR - //www.qdcxjkg.com/content/42/4/891.abstract N2 - Identifying and treating the eosinophilic subtype of asthma has now achieved renewed importance for clinicians and scientists involved in clinical trials. This has happened following the near-demise of an anti-interleukin (IL)-5 monoclonal antibody (mepolizumab) as a candidate for asthma treatment [1] and its resurrection in trials based around using induced sputum eosinophils to identify a treatment responsive phenotype [2, 3]. The improvement in outcome was spectacular. An effect size close to zero was converted to a massive effect size of a 50% reduction in asthma exacerbations, simply by using assessment of clinical status and eosinophils to identify a treatment responsive phenotype. The spotlight is now firmly on clinical trial design in airway diseases and how to identify disease subtypes for testing new therapies. An article by Dasgupta et al. [4], in this issue of the European Respiratory Journal, addresses this issue by reporting a systematic review of the use of one biomarker, sputum eosinophils, in randomised controlled trials over the past 10 years, and assesses the implications for study design, analysis and sample size in particular.For a long time, asthma pharmacotherapy has been based around β2-agonists and corticosteroids, which are regularly reformulated to tweak their clinical efficacy. The promise of new blockbuster treatments has remained both a hope and a necessity, but elusive. Basic scientists have elucidated … ER -